Top Page
Guangzhou Baiyunshan Pharmaceutical Holdings Company
(0874)
Guangzhou Baiyunshan Pharmaceutical Holdings Company (0874) vs. iShares MSCI Hong Kong ETF (EWH)
Guangzhou Baiyunshan Pharmaceutical Holdings Company Business Overview & Revenue Model
Guangzhou Baiyunshan Pharmaceutical Holdings Company Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 79.37B | 74.99B | 75.52B | 70.79B | 69.01B | 61.67B |
| Gross Profit | 13.20B | 12.52B | 14.19B | 13.28B | 13.23B | 10.44B |
| EBITDA | 4.60B | 4.90B | 6.49B | 6.22B | 5.82B | 4.68B |
| Net Income | 3.38B | 2.84B | 4.06B | 3.97B | 3.72B | 2.92B |
Balance Sheet | ||||||
| Total Assets | 90.90B | 81.68B | 78.59B | 74.67B | 66.12B | 59.76B |
| Cash, Cash Equivalents and Short-Term Investments | 20.04B | 22.72B | 21.31B | 22.56B | 22.38B | 19.47B |
| Total Debt | 22.73B | 12.37B | 11.70B | 11.43B | 9.92B | 9.56B |
| Total Liabilities | 47.20B | 43.91B | 41.91B | 41.03B | 34.79B | 31.55B |
| Stockholders Equity | 41.43B | 35.90B | 34.92B | 32.07B | 29.06B | 26.14B |
Cash Flow | ||||||
| Free Cash Flow | 1.37B | 2.31B | 2.48B | 5.62B | 4.42B | ― |
| Operating Cash Flow | -1.55B | 3.44B | 4.10B | 7.00B | 5.67B | 585.19M |
| Investing Cash Flow | -3.68B | -5.96B | -3.11B | ― | ― | ― |
| Financing Cash Flow | 924.18M | -1.01B | -1.98B | 45.95M | ― | 1.44B |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Technical Analysis
Guangzhou Baiyunshan Pharmaceutical Holdings Company Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$43.86B | 9.48 | 7.86% | 7.15% | 1.13% | -13.53% | |
73 Outperform | HK$28.04B | 13.30 | 12.65% | 3.13% | 10.56% | -13.58% | |
71 Outperform | HK$33.02B | 11.57 | 14.91% | 4.09% | -0.45% | 9.00% | |
68 Neutral | HK$28.96B | 9.52 | 5.90% | 2.95% | ― | ― | |
64 Neutral | HK$23.60B | 6.58 | 21.02% | 5.11% | 0.39% | 4.94% | |
53 Neutral | HK$76.85B | 15.87 | 6.75% | 1.69% | -1.12% | 76.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Corporate Events
Guangzhou Baiyunshan Pharmaceutical Holdings announced that its subsidiary GP Fund II has formally entered into and activated Partnership Agreement II with GP Capital, Angel Master Fund and Liwan Industrial Investment Fund to establish GP Liwan Fund as part of a previously disclosed connected transaction. The agreement, which took effect on 31 December 2025 with principal terms unchanged from the earlier disclosure, advances the company’s fund investment strategy and may enhance its ability to leverage financial partnerships for future pharmaceutical and related industrial investments, potentially strengthening its capital deployment and strategic positioning in the sector.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited announced that its third extraordinary general meeting of 2025, held on 30 December in Guangzhou, was duly convened in compliance with PRC company law and the firm’s articles of association, with most directors and senior management in attendance. All resolutions put to shareholders were passed by poll, with 647 shareholders present on-site or online representing about 53.7% of the company’s issued share capital, signaling broad shareholder participation and support and ensuring the continued corporate actions approved at the meeting carry a strong governance mandate.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings has confirmed that its subsidiary GP Fund II has formally entered into a partnership agreement with GP Capital and Guangkai Fund to establish GP Guangkai Fund, with the terms unchanged from those previously disclosed. The company noted that the separate partnership agreement to set up GP Liwan Fund has not yet been signed and pledged to update the market once it is completed, while cautioning shareholders and potential investors to exercise care when dealing in its securities until the remaining transaction progresses.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings announced that its consolidated subsidiary, Guangzhou Baiyunshan Biological Products Co., has received a drug registration certificate from China’s National Medical Products Administration for a lyophilized human rabies vaccine (Vero cell) for injection, classified as a preventive biological product. The approval, valid until December 2030, allows the subsidiary to act as both marketing authorization holder and manufacturer of the rabies vaccine, reinforcing the group’s position in the vaccine segment and potentially expanding its revenue base in the preventive healthcare market.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company has approved the participation of its subsidiary GP Fund II in establishing two new investment vehicles, GP Guangkai Fund and GP Liwan Fund, alongside related parties including GP Capital, Guangkai Fund, Angel Master Fund and Liwan Industrial Investment Fund. Under the approved arrangements, GP Fund II will contribute RMB97.5 million to GP Guangkai Fund and RMB99.5 million to GP Liwan Fund, both structured as limited partnerships with GP Capital acting as general partner and manager in certain roles, and with GP Guangkai Fund targeting a total fund size of RMB300 million and initial fundraising of RMB200 million. As GP Capital is controlled by the company’s controlling shareholder GPHL, the transactions are classified as connected transactions under Hong Kong Listing Rules, triggering reporting and announcement obligations but exempting them from independent shareholders’ approval, and the company has cautioned investors that the partnership agreements, although board-approved, have not yet been formally signed. These fund participations reinforce Baiyunshan’s use of venture-style capital structures to support sector-related investments while operating within the regulatory constraints on connected transactions, with limited immediate governance implications given the relatively small size of the deals in listing-rules terms.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company has signed a new continuing connected transactions agreement with its controlling shareholder Guangzhou Pharmaceutical Holdings Limited (GPHL) to govern a wide range of intra-group dealings from 1 January 2026 to 31 December 2026, replacing existing agreements that expire at the end of 2025. The new framework covers purchases and sales of pharmaceuticals and other goods, mutual provision and receipt of labour services such as advertising and R&D, entrusted processing arrangements, trademark and trade name licensing, and cross-leasing of properties and equipment, and is structured so that the anticipated transaction caps trigger reporting, announcement and annual review obligations under Hong Kong listing rules but remain exempt from independent shareholders’ approval, underscoring the regulated yet operationally integral nature of these related-party transactions for the group’s ongoing business with GPHL.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company, through its subsidiary GP Corp., announced the acquisition of 100% equity in a target company for RMB 500.50 million. This strategic investment strengthens its market positioning and highlights its commitment to growing operational scale, marking a significant step in expanding its footprint within the pharmaceutical sector.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company has announced the convening of its third extraordinary general meeting (EGM) in 2025, scheduled for December 30th. The meeting will address key resolutions including the asset-backed securitization of accounts receivable and the settlement of projects invested by proceeds, along with the permanent replenishment of working capital. This meeting is significant for stakeholders as it involves strategic financial decisions that could impact the company’s liquidity and financial management.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company announced a plan for GP Corp. to engage in account receivable asset-backed securitization, aiming to issue securities worth up to RMB3 billion. This strategic move is expected to enhance liquidity and optimize asset management, potentially strengthening the company’s financial position and market competitiveness.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company, through its subsidiary GP Corp., has entered into a transaction involving the disposal of accounts receivable to Industrial Securities Asset Management. This transaction, valued at RMB440,280,622.20, is part of a series of similar transactions conducted within a 12-month period. The aggregated transactions exceed a 5% threshold, making it a disclosable transaction under Hong Kong’s Listing Rules, subject to reporting and announcement requirements but exempt from shareholder approval.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited announced that its subsidiary, Guanghua, has entered into a Land Reserve Compensation Agreement with the Tonghe Sub-district Office for a land parcel located in Baiyun District, Guangzhou. The agreement entails a compensation amount of RMB375,244,134, with an additional land handover incentive of approximately RMB73,323,768, contingent upon meeting certain conditions. This agreement is part of the ‘Implementation Plan for Land Reserve in Baiyun Tonghe Area’ and could potentially impact the company’s operations by providing significant financial compensation, which may be used for future investments or operational enhancements.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited reported a significant increase in its financial performance for the third quarter of 2025. The company’s income from operations rose by 9.74% compared to the same period in 2024, and the net profit attributable to shareholders increased by 30.28%. Despite these positive results, the company experienced a substantial decrease in net cash flow from operating activities, which dropped by 162.45%. This financial report highlights the company’s strong profitability growth, although it faces challenges in cash flow management.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$20.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has revised the rules for its Nomination and Remuneration Committee to improve management structure and standardize procedures for appointing directors and senior management. These changes aim to ensure that the board members have the appropriate skills and diversity to support the company’s strategic goals. The committee will focus on formulating criteria for selecting and evaluating directors and senior management, as well as developing remuneration policies and plans. This move is expected to strengthen the company’s governance and align its leadership with its strategic objectives.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$20.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has approved a Board Diversity Policy to enhance corporate governance and support sustainable development. This policy emphasizes the importance of diversity in the boardroom, considering factors such as gender, age, cultural background, and professional experience in the selection of board members. The Nomination and Remuneration Committee is tasked with ensuring the implementation of this policy, with the aim of achieving a balanced and effective board composition. The company will report annually on the board’s diversity and the policy’s implementation, reflecting its commitment to inclusivity and strategic growth.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$20.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company has announced a supplementary disclosure regarding its acquisition of an 11.04% equity interest in a target company. The transaction involves a significant financial stake, with the book value of the equity attributable to the target shares being over 867 million RMB as of June 2025. The seller, AHAPL, is now indirectly owned by Blazing Star Investors, LLC, following a privatization and restructuring of its former parent company, Walgreens Boots Alliance. This acquisition is expected to impact the company’s market positioning and potential growth opportunities.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$20.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has announced a board meeting scheduled for October 28, 2025, to review and approve the unaudited financial results for the nine months ending September 30, 2025. This meeting is significant for stakeholders as it will provide insights into the company’s financial performance and potential strategic decisions moving forward.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.50 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.